Table 1.
Patient characteristics and laboratory data.
| All Patients n = 35 |
Monocyclic n = 13/32 ¥ |
Polycyclic n = 11/32 ¥ |
Chronic n = 8/32 ¥ |
p-Value | |||||
|---|---|---|---|---|---|---|---|---|---|
| Number (%) or Mean ± SD | |||||||||
| Female | 20 | (57.1) | 10 | (76.9) | 6 | (54.5) | 4 | (50.0) | NS |
| Male | 15 | (42.9) | 3 | (23.1) | 5 | (45.5) | 4 | (50.0) | NS |
| Age (year), mean ± SD | 46.2 ± 16.5 | 52.5 | ±16.1 | 34.0 | ±11.9 | 50.1 | ±17.3 | 0.031 | |
| Delay to diagnostic (months); mean (range) | 4.5 | (1–34) | 4.5 | (1–34) | 3 | (1–14) | 7.5 | (1–18) | 0.035 |
| Clinical features | |||||||||
| Fever | 35 | (100) | 13 | (100) | 11 | (100) | 8 | (100) | NS |
| Fever ≥ 39 °C * | 28/32 | (87.5) | 11 | (84.6) | 9 | (81.8) | 7 | (87.5) | NS |
| Arthralgia/arthritis | 32 | (91.4) | 12 | (92.3) | 11 | (100.0) | 8 | (100.0) | NS |
| Rash | 30 | (85.7) | 11 | (84.6) | 9 | (81.8) | 7 | (87.5) | NS |
| Sore throat/pharyngitis * | 24/32 | (75.0) | 12 | (92.3) | 7 | (63.6) | 5 | (62.5) | NS |
| Myalgia | 22 | (62.9) | 6 | (46.2) | 7 | (63.6) | 6 | (75.0) | NS |
| Clinical lymphadenopathy | 12 | (34.3) | 5 | (38.5) | 4 | (36.4) | 3 | (37.5) | NS |
| Clinical hepatomegaly | 6 | (17.1) | 0 | (0) | 5 | (45.5) | 0 | (0) | 0.004 |
| Clinical splenomegaly * | 5 | (15.6) | 1 | (7.7) | 4 | (36.4) | 0 | (0) | NS |
| Laboratory findings | |||||||||
| White blood cells > 10 G/L * | 27 | (77.1) | 9 | (69.2) | 10 | (90.9) | 7 | (87.5) | NS |
| Polymorphonuclear cells ≥ 80% | 19/28 | (67.9) | 6/11 | (54.5) | 9/10 | (90) | 4/7 | (57.1) | NS |
| CRP (mg/L); mean (range) | 137.8 | (17.4–417) | 131.3 | (25–373) | 155.4 | (17.4–417) | 129.1 | (20–391) | NS |
| Ferritin (ng/mL); mean (range) | 8635 | (98–92,200) | 14,710 | (98–92,200) | 5859 | (108–22,800) | 1507 | (107–2800) | NS |
| Glycosylated ferritin ≤ 20% * | 21/27 | (78) | 9/11 | (81.8) | 7/8 | (87.5) | 5 | (63) | NS |
| Elevated liver enzymes | 15 | (42.9) | 6 | (46.2) | 6 | (54.5) | 2 | (25.0) | NS |
| Negative for rheumatoid factor | 35 | (100) | 13 | (100) | 11 | (100) | 8 | (100) | NS |
| Antinuclear antibodies = 1/160 * | 5/33 | (15.2) | 2 | (16.7) | 1/10 | (10.0) | 1 | (12.5) | NS |
| Antinuclear antibodies > 1/160 * | 0/33 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | NS |
| Systemic score, mean ± SD | 5.2 ± 1.4 | 5.1 ± 1.4 | 5.6 ± 1.7 | 4.9 ± 0.8 | NS | ||||
Number (percentage) unless otherwise stated; * Number positive/number tested (percentage); ¥ Number positive/number tested; three patients could not be classified due to a lack of evolution data; CRP: C-reactive protein; Systemic score (range: 1–12) proposed by Pouchot et al. [14] assigns one point for each of the following manifestations: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function tests, splenomegaly, lymphadenopathy, leukocytosis > 15,000/mm3, sore throat, myalgia, and abdominal pain.